Newsletter

Generalized Myasthenia Gravis
A chronic autoimmune neuromuscular disease with almost 55% of the cases diagnosed in the US in the 7MM, gMG has managed to garner the attention of several pharma companies
Generalized Myasthenia Gravis Newsletter

More Whitepapers / Newsletters

ASCO Reveals: Increasing Options for Relapse/ Refractory Patients in Haematological Malignancies
ASCO Reveals: Increasing Optio...

Immunotherapies, a potentially life-saving therapy, have benefitted several patients suffering from cancer help to achieve complete remission that many other times, traditional chemotherapies fail to...

Consumer Healthcare during COVID-19
The Changing face of Consumer...

With worldwide dissemination and now over 9 million cases and nearly 500,000 deaths recorded, the effect of COVID-19 has been far-reaching and unpredictable. As people remain aware of new cases and de...

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Blastic Plasmacytoid Dendritic...

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare form of neoplasm, generally affects the elderly male population. Cancer develops in bone marrow and blood. It involves multiple...

Car-T Cell Therapy: A Journey From Challenges To Opportunities
Car-T Cell Therapy: A Journey...

With its innovative approach, chimeric antigen receptor T cell therapy created a new dawn in the age of cancer. Immunotherapy can be taken as a very powerful tool that can alter the immune system's pi...

Cancer In The United States(Vol 1, Issue 2)
Cancer In The United States(Vo...

US Cancer Statistics show that more than half a million suffer from this disease, which is the second leading cause of death in the country. The newsletter Cancer in the US substantiates the increasin...